Biotech Startups

ByBug is a biotech startup that uses genetic engineering and black soldier fly (Hermetia illucens) biomanufacturing to produce oral biological feed additives that prevent diseases such as Caligus in salmon and White Spot Syndrome Virus in shrimp. Its functional additives are mixed into existing animal feed for aquaculture producers, with a stated focus on the Chilean salmon industry and the global shrimp market.

3 investors

c-lecta introduces its management team and staff of over 130 employees. The page focuses on the company's personnel rather than describing its products or services in detail.

3 investors

Cadent Therapeutics was a Cambridge, Massachusetts-based neuroscience company developing clinical-stage therapies for neuropsychiatric disorders including schizophrenia, movement disorders, and treatment-resistant depression. The company was acquired by Novartis in 2021.

3 investors

Caedo Oncology develops therapeutic antibodies for cancer treatment, leveraging deep immunology and antibody engineering expertise.

3 investors

Cajal Therapeutics develops novel therapies through translating scientific advances into treatments for patients. The company is led by a team of experienced scientists and operators focused on drug discovery and development.

3 investors

Caldera is a clinical-stage biotechnology company developing CLD-423, a bispecific antibody targeting the IL-23p19 and TL1A pathways for inflammatory bowel disease and other immunologic and inflammatory diseases. Its lead candidate is in a Phase 1 healthy volunteer trial.

3 investors

Plant cell culture company producing cultivated cocoa and coffee without traditional crops.

3 investors

Callio Therapeutics develops next-generation dual-payload antibody-drug conjugates (ADCs) with differentiated payload and linker technologies for targeted cancer treatment. The company's lead program is a dual-payload HER2-targeted ADC designed to deliver drug combinations to tumor cells.

3 investors

Camp4 is a biotechnology company focused on genetic research and neurology, leveraging expertise in genomics and neuroscience for therapeutic development.

3 investors

Camstent develops coated medical devices using proprietary bacteriophobic polymer technology to reduce biofilm formation and infection risk on silicon-based medical devices, particularly catheters. The company addresses hospital-acquired infections, which represent a significant burden on healthcare systems and patient outcomes.

3 investors

Capacity Bio is a biotechnology company developing mitophagy modulators — small molecules, peptides, and nanoparticles that target mitochondrial biology to identify and clear dysfunctional mitochondria. Its pipeline includes a first-in-class mitophagy agonist intended for therapeutic use in aging- and disease-related conditions.

3 investors

Cardiac Dimensions develops medical technology to treat heart failure caused by functional mitral regurgitation (FMR), aiming to address underlying causes rather than symptoms. The company serves heart failure patients and clinicians, with operations in the United States, Australia, and Germany.

3 investors

CardioFocus develops Pulsed Field Ablation (PFA) technologies and systems for electrophysiologists to treat complex cardiac arrhythmias with precision and control. The company's portfolio includes the Centauri™ System and next-generation platforms designed for diverse ablation strategies in electrophysiology practices worldwide.

3 investors

CARI Health develops diagnostic solutions for medication monitoring, specifically focused on personalized methadone dosing for opioid use disorder treatment. The company combines clinical expertise with advanced diagnostic technology to address the opioid crisis.

3 investors

Caris Life Sciences is a precision medicine company focused on molecular profiling and research to support cancer care and improve patient outcomes. Founded in 2008, it collaborates with the healthcare industry through conferences, education, and research.

3 investors

Carthera develops SonoCloud®, an implantable ultrasound device that temporarily disrupts the blood-brain barrier to improve drug delivery to the brain for treatment of brain diseases including glioblastoma, brain metastases, and Alzheimer's Disease. The company's technology uses low-intensity pulsed ultrasound combined with microbubbles to increase therapeutic efficacy of existing and new therapies.

3 investors

Casma is a biotech company developing technology that uses the autophagy pathway to degrade disease targets for therapeutic applications. The company combines molecular biology expertise with a proprietary discovery platform to identify and eliminate disease-causing cellular elements.

3 investors

Castle Biosciences develops genomic diagnostic tests that use a patient's molecular biology to inform disease management and treatment decisions. Its tests serve healthcare providers and patients across multiple clinical focus areas to guide diagnosis, treatment, and follow-up care.

3 investors

Catalent is a global Contract Development and Manufacturing Organization (CDMO) that helps pharma, biotech, and self-care companies develop, manufacture, and deliver drug products and consumer health solutions. Its services span oral dose, biologics, specialty, and clinical supply, from early-stage design through commercial manufacturing.

3 investors

Catalyst OrthoScience develops medical devices and surgical techniques for shoulder replacement procedures, including total shoulder replacements and reverse shoulder arthroplasty. The company serves orthopedic surgeons and hospitals aiming to improve patient outcomes and surgical efficiency.

3 investors

Cavalry Biosciences is a biopharmaceutical company focused on developing medicines that leverage the body's inherent regenerative and repair mechanisms, particularly in areas of age-related disease and tissue regeneration. The company applies translational biology and drug development expertise across multiple therapeutic areas.

3 investors

Celaid Therapeutics develops hematopoietic stem cell expansion technology, including a method to replace albumin with polyvinyl alcohol and to expand human hematopoietic stem cells ex vivo in large quantities. The company applies this technology to stem cell transplantation and gene therapy for blood cancers such as leukemia and other blood and genetic diseases.

3 investors

Cellarity develops medicines using artificial intelligence and single-cell biology to address disease at the cellular level rather than targeting individual disease markers. The company serves patients with challenging diseases through AI-driven drug discovery.

3 investors

CellCo applies computational simulation, generative AI, and medicinal chemistry to design glycan-enabled therapeutics, engineering glycan ligands that direct RNA, small molecules, and antibodies to specific tissues and cell types. It develops platforms for molecular dynamics, synthetic data generation, and foundation models targeting glycan chemistry, immune modulation, and targeted drug delivery.

3 investors